Red Sox attempt to land Rich Harden from A’s, deal falls through

21 Comments

Now that the Ubaldo Jimenez sweepstakes have ended, other dominoes can begin falling.

Jayson Stark of ESPN.com passes along notice that the Red Sox are “closing in” on a deal for Athletics right-hander Rich Harden.

He doesn’t have the upside of Ubaldo, but Harden has posted a cool 30/10 K/BB ratio and 1.16 WHIP since returning from the disabled list in early July. The 29-year-old right-hander has a 3.65 career major league ERA and is owed less than $1 million through the end of the season.

The two sides are still talking, but an agreement could be reached at some point late Saturday night. Nick Cafardo of the Boston Globe is hearing that first base prospect Lars Anderson may be headed to Oakland.

UPDATE, 9:40 PM: Kevin Goldstein of Baseball Prospectus has the goods. The A’s will receive Anderson, who has a .782 OPS and 10 homers this year at Triple-A, and a player to be named later. The deal will be finalized on Sunday morning.

UPDATE, 1:10 AM: In a surprising turn of events, the trade has fallen through. Harden is scheduled to pitch for the A’s Tuesday against the Mariners and told reporters on Saturday night that he fully intends to make that start. Perhaps the Red Sox and A’s will revisit talks on Sunday morning.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.